Energy Secretary Jennifer Granholm visited ORNL on Nov. 22 for a two-hour tour, meeting top scientists and engineers as they highlighted projects and world-leading capabilities that address some of the country’s most complex research and technical challenges.
As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.
Four first-of-a-kind 3D-printed fuel assembly brackets, produced at the Department of Energy’s Manufacturing Demonstration Facility at Oak Ridge National Laboratory, have been installed and are now under routine operating
Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Oak Ridge National Laboratory expertise in fission and fusion has come together to form a new collaboration, the Fusion Energy Reactor Models Integrator, or FERMI
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
Toward the goal of bringing the next generation of nuclear power reactor technology online this decade, ORNL and Analysis and Measurement Services Corporation have successfully completed loop testing of instrument and control sensors for an advanced reactor design for small modular reactors.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.